Norditropin FlexPro receives FDA approval
By Alaric DeArment
PRINCETON, N.J. The Food and Drug Administration has approved a Novo Nordisk treatment for growth hormone disorders, the Danish drug maker announced Wednesday.
The agency approved Norditropin FlexPro (somatropin [rDNA origin]), a pre-filled injection pen for children and adults with growth hormone disorders. The drug is expected to become available in the second quarter.
The company said the pen was user-friendly, requiring no loading of cartridges and including an audible click to signify when the medication has left the pen.
Pfizer also makes a somatropin injection pen under the Genotropin brand, and generic drug maker Sandoz makes a biosimilar called Omnitrope.